Clinical Trial Update: Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating docetaxel plus doxorubicin for breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma of the Breast

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Sanofi | Conditions: Ductal Carcinoma | Phase 2 | Status: TERMINATED